Next generation sequencing has yielded an unparalleled means of quickly determining the molecular make-up of patient tumors. In conjunction with emerging, effective immunotherapeutics for a number of cancers, this rapid data generation necessitates a paired high-throughput means of predicting and assessing neoantigens from tumor variants that may stimulate immune response. Here we offer NeoPredPipe (Neoantigen Prediction Pipeline) as a contiguous means of predicting putative neoantigens and their corresponding recognition potentials for both single and multi-region tumor samples. NeoPredPipe is able to quickly provide summary information for researchers, and clinicians alike, on neoantigen burdens while providing high-level insights into tumor heterogeneity given somatic mutation calls and, optionally, patient HLA haplotypes. Given an example dataset we show how NeoPredPipe is able to rapidly provide insights into neoantigen heterogeneity, burden, and immune stimulation potential. Through the integration of widely adopted tools for neoantigen discovery NeoPredPipe offers a contiguous means of processing single and multi-region sequence data. NeoPredPipe is user-friendly and adaptable for high-throughput performance. NeoPredPipe is freely available at https://github.com/MathOnco/NeoPredPipe.
Introduction

1
Cancer cells are fraught with genomic variants in all regions of the genome with high 2 degrees of heterogeneity in a spatially complex tumor. This intra-tumor heterogeneity 3 (ITH) realizes a fitness landscape upon which natural selection can act (reviewed by [5] ). 4 Neoantigens, epitopes derived from proteins translated from non-synonymous variants, 5 are able to make their way to the cell surface in the hopes of stimulating an immune 6 response after a number of cellular processing steps have occurred, primarily 7 proteosomal cleavage and binding with major histocompatibility complexes (MHC) I or 8 II. This binding depends upon the patient specific human leukocyte antigen (HLA) 9 alleles. From here, the bound neoantigen with its MHC-Class I complex makes its way 10 
NeoPredPipe Workflow
25
Implementation
26
The first stage in neoantigen identification from a VCF file is the proper annotation of 27 variants to identify non-synonymous variants. To this end, NeoPredPipe employs the 28 widely used and efficient ANNOVAR ( [8] available HLA haplotypes prior to executing netMHCpan ( [7] ) for the primary 43 neoantigen predictions. As with the primary tool, the user is able to specify the epitope 44 to conduct predictions for (typically epitopes of 8-, 9-, or 10-mer lengths). The output supplied by the user as a fasta file (e.g. from Ensembl or UniProt).
52
The steps outlined above deliver candidate information for neoantigens from 53 provided variant calls that may be presented to cytotoxic T-Cells, however, this does 54 not inform the likelihood of a neoantigen eliciting an immune response (i.e. binds with a 55 TCR). In order to assess the recognition potential we employ the algorithms and 56 process utilized by [3] . The recognition potential is defined as the product of A and R, 57 where A is the amplitude of the ratio of the relative probabilities of binding for the 58 wildtype and mutant epitopes to the MHC-class I molecules, and R is the probability 59 that the neoantigen in question will be recognized by a TCR. To define A it is necessary 60 to perform neoantigen predictions for the wildtype and mutant epitope, this is not user, but is provided). In order to incorporate the ability to assess ITH in regards to 66 both effective mutations (non-synonymous variants) and neoantigen burdens,
67
NeoPredPipe is capable of handling multi-region VCF files; further these files can be 68 multi-region in only a select number of samples. Thus NeoPredPipe is able to efficiently 69 handle various experimental designs for neoantigen prediction and assessments 70 providing a summary table for downstream statistical and in-depth analysis.
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Results
72
The output of the pipeline depends largely on the options set by the user, but at the 
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for multi-region samples.
80
Use Case
81
While a small, two sample, multi-region example dataset is provided with the source 82 code for users, we demonstrate the usefulness of NeoPredPipe by applying it to a 83 previously published dataset examining the evolutionary landscape of colorectal 84 tumors [2] . We select two exemplary patient samples (Adenoma 3 and Carcinoma 7 in 85 the original paper) from the dataset, and apply our pipeline using default parameters to 86 evaluate neoantigens in each sample. Figure 2 illustrates the information included in the 87 standard output of NeoPredPipe and potential analysis that can be performed if
88
NeoPredPipe is combined with the output of other standard bioinformatic methods.
89 Figure 2A provides a summary of the complex interactions between different regions 90 of Adenoma 3, and highlights both Region 4, which harbours the highest amount of shows the recognition potential value for all neoantigens in the two samples.
101
NeoPredPipe identified 10 peptides in Adenoma 3 and 9 in Carcinoma 7 with a 102 recognition potential value above 1. In Figure 2D , we provide an example of integrating 103 NeoPredPipe outputs with downstream multi-region variant analysis. By inferring 104 phylogenetic trees of each tumor, constructed using all exonic mutations with a variant 105 allele frequency above 0.05 (see [2] for full methods), we find that neoantigen 
Conclusions
115
We present NeoPredPipe, an efficient, high-throughput, and user-friendly pipeline for 
